Beta-1,3/1,6-D-Glucan Extracted from Ganoderma lucidum as Adjunct Therapy in Ulcerative Colitis: A Case Series
), Marcellus Simadibrata(2), Rabbinu Rangga Pribadi(3), Virly Nanda Muzelina(4), Hasan Maulahela(5), Amanda Pitarini Utari(6), Enrik John Aguila(7), Ardhia Fefrine Indarta(8),
(1) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
(2) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
(3) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
(4) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
(5) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
(6) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
(7) Institute of Digestive and Liver Diseases, St. Luke’s Medical Center Global City, Taguig City, Philippines/ School of Medicine and Public Health, Ateneo de Manila University, Pasig City, Philippines
(8) Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
Corresponding Author
Abstract
The management of ulcerative colitis is primarily focused on the prevention of complications, remission sustenance, and enhancement of overall quality of life. However, long-term use of various pharmacological therapies can be associated with several side effects, including myelosuppression, hepatitis, lupus-like syndrome, and an increased risk of malignancy. These limitations have led to the search for safer therapeutic options, including bioactive compounds such as Beta-1,3/1,6-D-Glucan with immunomodulatory properties. Ganoderma lucidum contains Beta-1,3/1,6-D-Glucan as a principal bioactive compound extracted from its mycelium. Despite the broad therapeutic properties, exploration into its role specifically for ulcerative colitis patients remains scarce. Therefore, this case series aimed to explore the potential role of Beta-1,3/1,6-D-Glucan derived from Mycelium extract of Ganoderma lucidum in managing ulcerative colitis.
Keywords
References
Fakhoury M, Al-Salami H, Negrulj R, Mooranian A. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res [Internet]. 2014 Jun;113. Available from: http://www.dovepress.com/inflammatory-bowel-disease-clinical-aspects-and-treatments-peer-reviewed-article-JIR
Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med [Internet]. 2015;8(12):22529–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26885239
Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. Gastroenterology [Internet]. 2012 Jan;142(1):46–54.e42. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508511013783
Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res [Internet]. 2016;14(2):111. Available from: http://irjournal.org/journal/view.php?doi=10.5217/ir.2016.14.2.111
Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology [Internet]. 2013 Jul;145(1):158–165.e2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508513005003
Ng SC. Epidemiology of inflammatory bowel disease: Focus on Asia. Best Pract Res Clin Gastroenterol [Internet]. 2014 Jun;28(3):363–72. Available from: https://linkinghub.elsevier.com/retrieve/pii/S152169181400047X
Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology [Internet]. 2011 May;140(6):1827–1837.e2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508511001995
Liu C, Dunkin D, Lai J, Song Y, Ceballos C, Benkov K, et al. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn’s Disease Associated with Downregulation of NF-κB Signaling. Inflamm Bowel Dis [Internet]. 2015 Aug;21(8):1918–25. Available from: https://academic.oup.com/ibdjournal/article/21/8/1918-1925/4602954
Jin M, Zhu Y, Shao D, Zhao K, Xu C, Li Q, et al. Effects of polysaccharide from mycelia of Ganoderma lucidum on intestinal barrier functions of rats. Int J Biol Macromol [Internet]. 2017 Jan;94:1–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0141813016318244
Wang C, Shi S, Chen Q, Lin S, Wang R, Wang S, et al. Antitumor and Immunomodulatory Activities of Ganoderma lucidum Polysaccharides in Glioma-Bearing Rats. Integr Cancer Ther [Internet]. 2018 Sep 2;17(3):674–83. Available from: http://journals.sagepub.com/doi/10.1177/1534735418762537
Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, et al. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol [Internet]. 2022 Dec 3;22(1):92. Available from: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02157-5
Sharara AI, Malaeb M, Lenfant M, Ferrante M. Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication? Inflamm Intest Dis [Internet]. 2022;7(1):7–12. Available from: https://www.karger.com/Article/FullText/518131
Kim YG, Jang BI. The Role of Colonoscopy in Inflammatory Bowel Disease. Clin Endosc [Internet]. 2013;46(4):317. Available from: http://e-ce.org/journal/view.php?doi=10.5946/ce.2013.46.4.317
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol [Internet]. 2015 Sep;110(9):1324–38. Available from: https://journals.lww.com/00000434-201509000-00018
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohn’s Colitis [Internet]. 2022 Jan 28;16(1):2–17. Available from: https://academic.oup.com/ecco-jcc/article/16/1/2/6390052
Li T, Qian Y, Bai T, Li J. Prediction of complications in inflammatory bowel disease using routine blood parameters at diagnosis. Ann Transl Med [Internet]. 2022 Feb;10(4):185–185. Available from: https://atm.amegroups.com/article/view/90233/html
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohn’s Colitis [Internet]. 2017 Jul 1;11(7):769–84. Available from: https://academic.oup.com/ecco-jcc/article/11/7/769/2962457
Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med [Internet]. 2022 Apr 20;11(9):2302. Available from: https://www.mdpi.com/2077-0383/11/9/2302
Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev [Internet]. 2016 May 9. Available from: https://doi.wiley.com/10.1002/14651858.CD000544.pub4
Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol [Internet]. 2008;14(3):354. Available from: http://www.wjgnet.com/1007-9327/full/v14/i3/354.htm
Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu T, Yajima T, et al. 5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. Intest Res [Internet]. 2018 Oct 30;16(4):635–40. Available from: http://irjournal.org/journal/view.php?doi=10.5217/ir.2018.00015
Garud S, Peppercorn MA. Review: Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol [Internet]. 2009 Mar 1;2(2):99–108. Available from: http://journals.sagepub.com/doi/10.1177/1756283X09102329
Selinger CP, Parkes GC, Bassi A, Limdi JK, Ludlow H, Patel P, et al. Assessment of steroid use as a key performance indicator in inflammatory bowel disease—analysis of data from 2385 UK patients. Aliment Pharmacol Ther [Internet]. 2019 Nov 8;50(9):1009–18. Available from: https://onlinelibrary.wiley.com/doi/10.1111/apt.15497
Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol [Internet]. 2018 Mar;113(3):405–17. Available from: https://journals.lww.com/00000434-201803000-00018
Hazenberg HMJL, de Boer NKH, Mulder CJJ, Mom SH, van Bodegraven AA, Tack GJ. Neoplasia and Precursor Lesions of the Female Genital Tract in IBD: Epidemiology, Role of Immunosuppressants, and Clinical Implications. Inflamm Bowel Dis [Internet]. 2018 Feb 16;24(3):510–31. Available from: https://academic.oup.com/ibdjournal/article/24/3/510/4863709
Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. J Crohn’s Colitis [Internet]. 2016 Aug;10(8):989–97. Available from: https://academic.oup.com/ecco-jcc/article-lookup/doi/10.1093/ecco-jcc/jjw053
Lin ZB. Cellular and Molecular Mechanisms of Immunomodulation by Ganoderma lucidum. J Pharmacol Sci [Internet]. 2005;99(2):144–53. Available from: https://www.jstage.jst.go.jp/article/jphs/99/2/99_2_144/_article
Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum Polysaccharides: Immunomodulation and Potential Anti-Tumor Activities. Am J Chin Med [Internet]. 2011 Jan 5;39(01):15–27. Available from: https://www.worldscientific.com/doi/abs/10.1142/S0192415X11008610
Wei B, Zhang R, Zhai J, Zhu J, Yang F, Yue D, et al. Suppression of Th17 Cell Response in the Alleviation of Dextran Sulfate Sodium-Induced Colitis by Ganoderma lucidum Polysaccharides. J Immunol Res [Internet]. 2018;2018:1–10. Available from: https://www.hindawi.com/journals/jir/2018/2906494/
Guo C, Guo D, Fang L, Sang T, Wu J, Guo C, et al. Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon. Carbohydr Polym [Internet]. 2021 Sep;267:118231. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0144861721006184
Xie J, Liu Y, Chen B, Zhang G, Ou S, Luo J, et al. Ganoderma lucidum polysaccharide improves rat DSS-induced colitis by altering cecal microbiota and gene expression of colonic epithelial cells. Food Nutr Res [Internet]. 2019 Feb 12;63. Available from: http://www.foodandnutritionresearch.net/index.php/fnr/article/view/1559
Article Metrics
Abstract View
: 53 times
Download : 42 times
DOI: 10.24871/2722026204-211
Refbacks
- There are currently no refbacks.
